Holen Sie sich die Stockscreener-App
7.94
1.40%
0.11
Handel nachbörslich:
7.95
0.010
+0.13%
Diamedica Therapeutics Inc Aktie (DMAC) Neueste Nachrichten
Avoiding Lag: Real-Time Signals in (DMAC) Movement - Stock Traders Daily
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - Eastern Progress
DiaMedica Therapeutics Inc. (DMAC) Key Financial Ratios – Valuation, Profitability & More - Value Research
(DMAC) Risk Channels and Responsive Allocation - Stock Traders Daily
Price to earnings forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
(DMAC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
DMAC Q2 2026 Earnings: Narrower-than-Expected Loss of $0.19 per ShareEPS Growth Rate - careplusvn.com
DiaMedica Therapeutics Inc. (DMAC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Four New York investor talks are planned for September by DiaMedica - Stock Titan
Zomedica Corp. (ZOM) Peer Comparison – Compare with Others - Value Research
DiaMedica Therapeutics Inc. (DMAC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
InMed Pharmaceuticals Inc. (INM) Peer Comparison – Compare with Others - Value Research
Understanding the Setup: (DMAC) and Scalable Risk - Stock Traders Daily
DiaMedica Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
DiaMedica (DMAC) Results Versus Estimates: EPS Lands Above Forecast; Share Response: The Market Price Advances 1.82% in the Current UpdateManagement Tone Analysis - vinanet.vn
DiaMedica Therapeutics Inc (DMAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
META_TITLE_QUOTE - Yahoo Finance
DiaMedica's DM199: Multiple Catalysts AheadWill It Deliver? - RTTNews
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript - AOL.com
DMAC Q2 2026 Earnings: Narrower-Than-Expected Loss Reflects Disciplined SpendingEBITDA Estimate Trend - Vinanet
DMAC Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline as Pipeline AdvancesEarnings Expansion Phase - dars.gov.et
DiaMedica Therapeutics (DMAC) Slips 1.04% as Shares Consolidate Between $6.35 Support and $7.01 ResistanceBPI Bear Correction - vinanet.vn
DiaMedica Therapeutics (DMAC) Edges Lower as Shares Consolidate Within Established RangeWatchlist Stock Ideas - vinanet.vn
All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy - Yahoo Finance
What is HC Wainwright's Estimate for DMAC Q3 Earnings? - MarketBeat
DiaMedica Therapeutics Inc. (DMAC) stock price, news, quote and history - Yahoo Finance UK
DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years - Stock Titan
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration - The Globe and Mail
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ... - Yahoo Finance
DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highli - GuruFocus
DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
DiaMedica Therapeutics (DMAC) Advances Clinical Trials Amid High Price-to-Sales Valuation - GuruFocus
DiaMedica Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
DMAC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
HC Wainwright Reaffirms Buy Rating for DiaMedica Therapeutics (NASDAQ:DMAC) - MarketBeat
DiaMedica Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: DiaMedica Q2 2026 loss matches forecast as trials advance - Investing.com
DiaMedica Therapeutics Reports Q2 2026 Form 10-Q Highlighting Clinical Trial Enrollment Challenges - Kalkine Media
DiaMedica Advances Key Phase 2 Programs and Extends Cash Runway Through 2027 - TipRanks
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - BioSpace
DiaMedica Therapeutics (DMAC) Reports Positive Interim Data, Mar - GuruFocus
DiaMedica Q2 net loss widens to $10.1M as DM199 shows clinical promise - scanx.trade
DiaMedica Therapeutics (NASDAQ:DMAC) Issues Quarterly Earnings Results - MarketBeat
DiaMedica Therapeutics reports Q2 net loss $10.1M, cash $43.5M; advances DM199 clinical programs - TradingView
DiaMedica reports $10.1 million Q2 loss as DM199 trials advance - Quiver Quantitative
DiaMedica Therapeutics (NASDAQ: DMAC) increases R&D spend and loss in Q2 2026 - Stock Titan
DiaMedica Therapeutics (DMAC) Slips to $6.75 as Biotech Stock Consolidates Between Key Support and ResistanceNAAIM Exposure - careplusvn.com
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
DiaMedica Therapeutics Inc (DMAC) Stock News Today - TradingKey
(DMAC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Press Release: DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights - 富途牛牛
DiaMedica Therapeutics Inc (DMAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
DiaMedica Therapeutics (DMAC) Climbs 2.91% to $6.73: Key Levels and What to WatchAggressive Growth Picks - careplusvn.com
Press Release: DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Moomoo
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire
DiaMedica Therapeutics (DMAC) Expected to Post Earnings on Tuesday - MarketBeat
1 Main Capital Highlights DiaMedica Therapeutics in Q2 2026 Letter - sekbernews.id
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential - Yahoo Finance
DMAC Q1 2026 Earnings: Narrow Miss as Clinical-Stage Losses PersistPositive Surprise Momentum - dars.gov.et
DiaMedica Therapeutics Inc (DMAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 1.5%Should You Sell? - MarketBeat
DMAC|DiaMedica Therapeutics Inc|Price:6.720|Chg%:-0.015 - TradingKey
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):